JP2022542884A - Fcrnアンタゴニストで抗体媒介性障害を処置する方法 - Google Patents

Fcrnアンタゴニストで抗体媒介性障害を処置する方法 Download PDF

Info

Publication number
JP2022542884A
JP2022542884A JP2022504569A JP2022504569A JP2022542884A JP 2022542884 A JP2022542884 A JP 2022542884A JP 2022504569 A JP2022504569 A JP 2022504569A JP 2022504569 A JP2022504569 A JP 2022504569A JP 2022542884 A JP2022542884 A JP 2022542884A
Authority
JP
Japan
Prior art keywords
amino acid
fcrn
acid position
binding
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022504569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542884A5 (cg-RX-API-DMAC7.html
Inventor
ブリアン・マックネス
ファウェイ・チウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2022542884A publication Critical patent/JP2022542884A/ja
Publication of JP2022542884A5 publication Critical patent/JP2022542884A5/ja
Priority to JP2025051382A priority Critical patent/JP2025098167A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022504569A 2019-07-25 2020-07-24 Fcrnアンタゴニストで抗体媒介性障害を処置する方法 Pending JP2022542884A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025051382A JP2025098167A (ja) 2019-07-25 2025-03-26 Fcrnアンタゴニストで抗体媒介性障害を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878541P 2019-07-25 2019-07-25
US62/878,541 2019-07-25
PCT/US2020/043533 WO2021016571A2 (en) 2019-07-25 2020-07-24 Methods of treating antibody-mediated disorders with fcrn antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025051382A Division JP2025098167A (ja) 2019-07-25 2025-03-26 Fcrnアンタゴニストで抗体媒介性障害を処置する方法

Publications (2)

Publication Number Publication Date
JP2022542884A true JP2022542884A (ja) 2022-10-07
JP2022542884A5 JP2022542884A5 (cg-RX-API-DMAC7.html) 2023-07-31

Family

ID=72087159

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022504569A Pending JP2022542884A (ja) 2019-07-25 2020-07-24 Fcrnアンタゴニストで抗体媒介性障害を処置する方法
JP2025051382A Pending JP2025098167A (ja) 2019-07-25 2025-03-26 Fcrnアンタゴニストで抗体媒介性障害を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025051382A Pending JP2025098167A (ja) 2019-07-25 2025-03-26 Fcrnアンタゴニストで抗体媒介性障害を処置する方法

Country Status (13)

Country Link
US (1) US12655200B2 (cg-RX-API-DMAC7.html)
EP (1) EP4004039A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022542884A (cg-RX-API-DMAC7.html)
KR (1) KR20220038432A (cg-RX-API-DMAC7.html)
CN (2) CN114466663B (cg-RX-API-DMAC7.html)
AU (1) AU2020315925A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001255A2 (cg-RX-API-DMAC7.html)
CA (1) CA3148764A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001164A2 (cg-RX-API-DMAC7.html)
IL (1) IL290101A (cg-RX-API-DMAC7.html)
MX (1) MX2022001038A (cg-RX-API-DMAC7.html)
TW (1) TW202120539A (cg-RX-API-DMAC7.html)
WO (1) WO2021016571A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023313033A1 (en) 2022-07-27 2025-03-13 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
TW202525845A (zh) 2023-08-23 2025-07-01 法商賽諾菲公司 基於ctla—4之溶體降解劑及其用途
WO2025088546A1 (en) 2023-10-25 2025-05-01 Ablynx N.V. Fc domain variants with enhanced fc receptor binding
IL328245A (en) 2023-11-08 2026-07-01 Sanofi Sa CD25-based lysosomal compartment and its uses
AU2024413168A1 (en) * 2023-12-27 2026-07-16 Vetmab Biosciences, Inc. FcRn ANTAGONISTS FOR VETERINARY USE
WO2026133288A2 (en) 2024-12-20 2026-06-25 Sanofi IL-2RβΥ BASED LYSOSOMAL DEGRADER AND USES THEREOF
WO2026133294A1 (en) 2024-12-20 2026-06-25 Sanofi Pd-1/gitr multispecific binding polypeptides and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519860A (ja) * 2004-11-12 2008-06-12 ゼンコー・インコーポレイテッド FcRnとの変化した結合を有するFc変異体
WO2013047748A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP2014528906A (ja) * 2011-09-30 2014-10-30 中外製薬株式会社 抗原クリアランスを促進するFcRn結合ドメインを有する治療用抗原結合分子
JP2018509413A (ja) * 2015-03-09 2018-04-05 アルゲン−エックス ビーブイビーエー FcRnアンタゴニストを用いてFc含有剤の血清レベルを低下させる方法
WO2019110823A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
JP2021511830A (ja) * 2018-01-26 2021-05-13 ジェンザイム・コーポレーション FcRnへの増強された結合及び延長された半減期を有するFc変異体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
JP4762156B2 (ja) 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション,インコーポレイテッド Fc領域変異体
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
ES2573642T3 (es) 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX2013011366A (es) * 2011-03-30 2014-05-12 Chugai Pharmaceutical Co Ltd Retencion de las moleculas de union al antigeno en el plasma sanguineo y metodo para modificar la inmunogenicidad.
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
CA2871934C (en) 2012-04-30 2023-06-13 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
CA2904805A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
CN106103476B (zh) 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
US20170211876A1 (en) 2014-06-12 2017-07-27 Hoffmann-La Roche Inc. Method for selecting antibodies with modified fcrn interaction
RU2713131C1 (ru) 2014-11-06 2020-02-03 Ф. Хоффманн-Ля Рош Аг ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А
PT3215528T (pt) * 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
SG11201702550WA (en) 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
CA3022547A1 (en) 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
WO2018213097A1 (en) * 2017-05-15 2018-11-22 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519860A (ja) * 2004-11-12 2008-06-12 ゼンコー・インコーポレイテッド FcRnとの変化した結合を有するFc変異体
WO2013047748A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP2014528906A (ja) * 2011-09-30 2014-10-30 中外製薬株式会社 抗原クリアランスを促進するFcRn結合ドメインを有する治療用抗原結合分子
JP2018509413A (ja) * 2015-03-09 2018-04-05 アルゲン−エックス ビーブイビーエー FcRnアンタゴニストを用いてFc含有剤の血清レベルを低下させる方法
WO2019110823A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
JP2021511830A (ja) * 2018-01-26 2021-05-13 ジェンザイム・コーポレーション FcRnへの増強された結合及び延長された半減期を有するFc変異体
JP7399880B2 (ja) * 2018-01-26 2023-12-18 ジェンザイム・コーポレーション FcRnへの増強された結合及び延長された半減期を有するFc変異体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J OF NUCLEAR MEDICINE, vol. 55, no. 7, JPN6024023906, 2014, pages 1204 - 1207, ISSN: 0005643535 *
MABS, vol. 11, no. 7, JPN6024023905, 18 July 2019 (2019-07-18), pages 1276 - 1288, ISSN: 0005643536 *

Also Published As

Publication number Publication date
CO2022001164A2 (es) 2022-03-08
JP2025098167A (ja) 2025-07-01
IL290101A (en) 2022-03-01
EP4004039A2 (en) 2022-06-01
TW202120539A (zh) 2021-06-01
CN114466663A (zh) 2022-05-10
US20210024620A1 (en) 2021-01-28
US12655200B2 (en) 2026-06-16
WO2021016571A3 (en) 2021-03-04
KR20220038432A (ko) 2022-03-28
CA3148764A1 (en) 2021-01-28
CN114466663B (zh) 2026-01-02
WO2021016571A2 (en) 2021-01-28
CN122272792A (zh) 2026-06-26
AU2020315925A1 (en) 2022-03-03
BR112022001255A2 (pt) 2022-06-14
MX2022001038A (es) 2022-04-26

Similar Documents

Publication Publication Date Title
JP7399880B2 (ja) FcRnへの増強された結合及び延長された半減期を有するFc変異体
JP2025098167A (ja) Fcrnアンタゴニストで抗体媒介性障害を処置する方法
JP7631276B2 (ja) Vegf-a及びang2に結合する抗体及び使用方法
TW202003570A (zh) 抗trem-1抗體及其用途
AU2018382593A1 (en) Variants with Fc fragment having an increased affinity for FcRn and an increased affinity for at least one receptor of the Fc fragment
JP6522585B2 (ja) Cxcr5に対するモノクローナル抗体
CN115175736A (zh) 杂交抗体
TW202607021A (zh) 結合tslp之抗體及使用方法
WO2022061236A1 (en) High affinity anti-ige antibodies
TW202306584A (zh) 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體
RU2795592C2 (ru) Варианты fc с повышенным связыванием с fcrn и пролонгированным периодом полувыведения
BR122024014725A2 (pt) Usos de um antagonista de fcrn no tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn, polipeptídeos isolados, e composições farmacêuticas compreendendo os mesmos
HK40086991A (en) Antibody that binds to vegf-a and ang2 and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326